- Home
- BDRX vs ADXN Comparison
BDRX vs ADXN Comparison
Compare BDRX & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- ADXN
- Stock Information
- Founded
- BDRX 2000
- ADXN 2002
- Country
- BDRX United Kingdom
- ADXN Switzerland
- Employees
- BDRX N/A
- ADXN N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- ADXN Health Care
- Exchange
- BDRX Nasdaq
- ADXN Nasdaq
- Market Cap
- BDRX 5.8M
- ADXN 10.1M
- IPO Year
- BDRX N/A
- ADXN N/A
- Fundamental
- Price
- BDRX $0.88
- ADXN $9.00
- Analyst Decision
- BDRX
- ADXN Strong Buy
- Analyst Count
- BDRX 0
- ADXN 1
- Target Price
- BDRX N/A
- ADXN $30.00
- AVG Volume (30 Days)
- BDRX 4.2M
- ADXN 14.3K
- Earning Date
- BDRX 04-11-2025
- ADXN 08-11-2025
- Dividend Yield
- BDRX N/A
- ADXN N/A
- EPS Growth
- BDRX N/A
- ADXN N/A
- EPS
- BDRX N/A
- ADXN 0.10
- Revenue
- BDRX N/A
- ADXN $278,508.00
- Revenue This Year
- BDRX N/A
- ADXN $86.57
- Revenue Next Year
- BDRX N/A
- ADXN N/A
- P/E Ratio
- BDRX N/A
- ADXN $0.75
- Revenue Growth
- BDRX N/A
- ADXN N/A
- 52 Week Low
- BDRX $0.78
- ADXN $6.51
- 52 Week High
- BDRX $30.00
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- BDRX 42.16
- ADXN 51.86
- Support Level
- BDRX $0.82
- ADXN $8.78
- Resistance Level
- BDRX $1.33
- ADXN $9.89
- Average True Range (ATR)
- BDRX 0.09
- ADXN 0.54
- MACD
- BDRX 0.02
- ADXN -0.05
- Stochastic Oscillator
- BDRX 11.75
- ADXN 35.97
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.